Person:
KAZAK, ESRA

Loading...
Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Organizational Unit

Job Title

Last Name

KAZAK

First Name

ESRA

Name

Search Results

Now showing 1 - 10 of 23
  • Publication
    The distribution of mature and/or immature myeloid cells and their role in effective anti-viral immune responses in COVID-19 positive patients
    (Wiley, 2021-08-01) Ermiş, Diğdem Yöyen; Dömbaz, Fatma; Karaçay, Mehmet; Etgü, Onur; Kızmaz, Muhammed Ali; Şimşek, Abdurrahman; Çağan, Eren; Aşan, Ali; Yılmaz, Emel; Kazak, Esra; Pınar, İbrahim Ethem; Bal, Salih Haldun; Arslan, Gözde; Karaca, Mert; Özkocaman, Vildan; Özkalemtaş, Fahir; Akalın, Emin Halis; Budak, Ferah; Oral, Haluk Barbaros; YÖYEN ERMİŞ, DİĞDEM; Dombaz, Fatma; Karaçay, Mehmet; Etgü, Onur; Kızmaz, Muhammed Ali; ŞİMŞEK, ABDURRAHMAN; YILMAZ, EMEL; KAZAK, ESRA; PINAR, İBRAHİM ETHEM; BAL, SALİH HALDUN; Arslan, Gözde; KARACA, MERT; ÖZKOCAMAN, VİLDAN; Özkalemtaş, Fahir; AKALIN, EMİN HALİS; BUDAK, FERAH; ORAL, HALUK BARBAROS; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İmmünoloji Ana Bilim Dalı.; Bursa Uludağ Üniversitesi/Sağlık Bilimleri Enstitüsü.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Rasit Durusoy Kan Bankası.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Hemotoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı.; 0000-0001-7288-3250; 0000-0001-5334-7911; 0000-0001-8850-0269; 0000-0002-8856-7356; 0000-0003-1785-3539; 0000-0001-7530-1279; 0000-0001-7625-9148; 0000-0003-0463-6818; KHE-5423-2024; AAU-8952-2020; HKN-2347-2023; JGM-6601-2023; JFS-2013-2023; AAG-7381-2021; K-7285-2012; IZP-9398-2023; F-4657-2014; JWP-2738-2024; GYL-2038-2022; DWR-5356-2022; CXY-4200-2022; CPT-2053-2022; GDP-0005-2022; AAG-8459-2021; FQJ-3657-2022; FQG-8981-2022
  • Publication
    Risk factors for occupational brucellosis among veterinary personnel in turkey
    (Elsevier Science Bv, 2014-11-01) Kutlu, Murat; Ergonul, Onder; Sayin-Kutlu, Selda; Guven, Tumer; Ustun, Cemal; Alp-Cavuş, Sema; Öztürk, Şerife Baron; Acicbe, Özlem; Akalın, Şerife; Tekin, Recep; Tekin-Koruk, Suda; Demiroğlu, Yusuf Ziya; Keskiner, Ramazan; Gönen, Ibak; Sapmaz-Karabağ, Sevil; Boşnak, Vuslat; Kazak, Esra; KAZAK, ESRA; Bursa Uludağ Üniversitesi/Tıp Fakültesi; AAG-8459-2021
    Veterinarians and veterinary technicians are at risk for occupational brucellosis. We described the risk factors of occupational brucellosis among veterinary personnel in Turkey. A multicenter retrospective survey was performed among veterinary personnel who were actively working in the field. Of 712 veterinary personnel, 84(11.8%) had occupational brucellosis. The median number of years since graduation was 7 (interquartile ranges [IQR], 4-11) years in the occupational brucellosis group, whereas this number was 9 (IQR, 4-16) years in the non-brucellosis group (p < 0.001). In multivariable analysis, working in the private sector (odds ratio [OR], 2.8; 95% confidence interval [95% CI], 1.55-5.28, p = 0.001), being male (OR, 4.5; 95% CI, 1.05-18.84, p = 0.041), number of performed deliveries (OR, 1.01; 95% CI, 1.002-1.02, p = 0.014), and injury during Brucella vaccine administration (OR, 5.4; 95% CI, 3.16-9.3, p < 0.001) were found to be risk factors for occupational brucellosis. We suggest that all veterinary personnel should be trained on brucellosis and the importance of using personal protective equipment in order to avoid this infection. (C) 2014 Elsevier B.V. All rights reserved.
  • Publication
    Macrophage polarization capacity of peripheral blood monocytes and monocytic cell line THP-1 in response to secreted factors from COVID-19 patients
    (Wiley, 2021-08-01) Etgü, Onur; Karaçay, Mehmet; Dombaz, Fatma; Kızmaz, Muhammed Ali; Şimsek, Abdurrahman; Asan, Ali; Yılmaz, Emel; Kazak, Esra; Pınar, İbrahim Ethem; Bal, Salih Haldün; Özkocaman, Vildan; Özkalemkaş, Fahir; Akalın, Emin Halis; Budak, Ferah; Oral, Haluk Barbaros; Ermiş, Diğdem Yöyen; Etgü, Onur; Karaçay, Mehmet; Dombaz, Fatma; Kızmaz, Muhammed Ali; ŞİMŞEK, ABDURRAHMAN; YILMAZ, EMEL; KAZAK, ESRA; PINAR, İBRAHİM ETHEM; BAL, SALİH HALDUN; ÖZKOCAMAN, VİLDAN; ÖZKALEMKAŞ, FAHİR; AKALIN, EMİN HALİS; BUDAK, FERAH; ORAL, HALUK BARBAROS; YÖYEN ERMİŞ, DİĞDEM; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İmmünoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Temel Tıp Bilimleri Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Dr Raşit Durusoy Kan Bankası.; 0000-0001-7288-3250; 0000-0001-5334-7911; 0000-0001-8850-0269; 0000-0002-8856-7356; 0000-0003-1785-3539; 0000-0001-9907-1498; 0000-0001-7530-1279; 0000-0001-7625-9148; 0000-0003-0463-6818; JIJ-1849-2023; JHB-7829-2023; DWR-5356-2022; HKN-2347-2023; AAG-7381-2021; GDP-0005-2022; AAG-8459-2021; JGM-6601-2023; KBR-5535-2024; FQG-8981-2022; JIW-1248-2023; AAU-8952-2020; IZP-9398-2023; K-7285-2012; GYL-2038-2022
  • Publication
    Prognostic factors for COVID-19 patients
    (J Infection Developing Countries, 2022-03-01) Önal, Uğur; Güçlü, Özge Aydın; Akalın, Halis; Öztürk, Nilüfer Aylin Acet; Semet, Cihan; Demirdoğen, Ezgi; Dilektaşlı, Aslı Görek; Sağlık, İmran; Kazak, Esra; Özkaya, Güven; Coşkun, Funda; Ediger, Dane; Heper, Yasemin; Ursavaş, Ahmet; Yılmaz, Emel; Uzaslan, Esra; Karadağ, Mehmet; ÖNAL, UĞUR; AYDIN GÜÇLÜ, ÖZGE; AKALIN, EMİN HALİS; ACET ÖZTÜRK, NİLÜFER AYLİN; SEMET, CİHAN; DEMİRDÖĞEN, EZGİ; GÖREK DİLEKTAŞLI, ASLI; SAĞLIK, İMRAN; KAZAK, ESRA; ÖZKAYA, GÜVEN; COŞKUN, NECMİYE FUNDA; EDİGER, DANE; HEPER, YASEMİN; URSAVAŞ, AHMET; YILMAZ, EMEL; UZASLAN, AYŞE ESRA; KARADAĞ, MEHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Mikrobiyoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.; 0000-0001-6194-3254; 0000-0003-1005-3205; 0000-0001-7530-1279; 0000-0002-6375-1472; 0000-0002-7400-9089; 0000-0001-7099-9647; 0000-0003-0864-4989; 0000-0003-0297-846X; 0000-0003-3604-8826; 0000-0002-2954-4293; 0000-0002-3894-1231; 0000-0002-9027-1132; A-4421-2016; AAG-8459-2021; GCM-3391-2022; DTT-7416-2022; AAH-9812-2021; AEA-4817-2022; Z-1424-2019; AAU-8952-2020; AAG-9930-2019; ACQ-7832-2022; AAD-1271-2019; AAE-9142-2019; CTY-9474-2022; AAI-3169-2021; HJZ-6992-2023; CDI-1977-2022; AAG-8744-2021
    Introduction: Determining prognostic factors in patients with coronavirus disease (COVID-19) can have great impact on treatment planning and follow-up strategies. Herein, we aimed to evaluate prognostic factors and clinical scores for confirmed COVID-19 patients in a tertiary care hospital in the Bursa region of Turkey. Methodology: Patients who had been diagnosed with COVID-19 microbiologically and/or radiologically between March and October 2020 in a tertiary-care university hospital were enrolled retrospectively. Adult patients (>= 18 years) with a clinical spectrum of moderate, severe, or critical illness were included. The dependent variable was 30-day mortality and logistic regression analysis was used to evaluate any variables with a significant p value (< 0.05) in univariate analysis. Results: A total of 257 patients were included in the study. The mortality rate (30-day) was 14.4%. In logistic regression analysis, higher scores on sequential organ failure assessment (SOFA) (p < 0.001, odds ratio (OR) = 1.86, 95% CI = 1.42-2.45) and CURB-65 pneumonia severity criteria (p = 0.001, OR = 2.60, 95% CI = 1.47-4.57) were found to be significant in predicting mortality at admission. In deceased patients, there were also significant differences between the baseline, day-3, day-7, and day-14 results of D-dimer (p = 0.01), ferritin (p = 0.042), leukocyte (p = 0.019), and neutrophil (p = 0.007) counts. Conclusions: In our study of COVID-19 patients, we found that high SOFA and CURB-65 scores on admission were associated with increased mortality. In addition, D-dimer, ferritin, leukocyte and neutrophil counts significantly increased after admission in patients who died.
  • Publication
    Experience of pandemic influenza A (H1N1) 2009
    (Aves, 2012-12-01) Kebabçı, Nesrin; Akalın, Halis; Bölük, Gülçin; Oğuz-Ayarcı, Ayşe; Kazak, Esra; Topal, Uğur; Yorulmaz, Hakan; Akköse, Şule; Özvatan-Şener, Tülay; Aslan, Emel; Köprücüoğlu, Duygu; Heper, Yasemin; Yılmaz, Emel; Kahveci, Ferda; Mıstık, Reşit; Helvacı, Safiye; Kebabçı, Nesrin; AKALIN, EMİN HALİS; Bölük, Gülçin; Oğuz-Ayarcı, Ayşe; KAZAK, ESRA; Topal, Uğur; Yorulmaz, Hakan; Akköse, Şule; Özvatan-Şener, Tülay; Aslan, Emel; Köprücüoğlu, Duygu; HEPER, YASEMİN; YILMAZ, EMEL; KAHVECİ, FERDA ŞÖHRET; Mıstık, Reşit; Helvacı, Safiye; Uludağ Üniversitesi/Tıp Fakültesi/İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Radyoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Acil Tıp Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Anesteziyoloji ve Reanimasyon Anabilim Dalı.; 0000-0001-7530-1279; 0000-0002-3894-1231; 0000-0003-4820-2288; FCW-3335-2022; AAU-8952-2020; KFT-0453-2024; FOZ-1105-2022; AAG-8459-2021; JLP-0593-2023; EIO-1059-2022; EJV-1316-2022; FQE-4671-2022; EJJ-4181-2022; FGO-0266-2022; AAH-6506-2021; HJZ-6992-2023; AAG-9356-2021; DFY-3761-2022; EXQ-2687-2022
    Objective: Pandemic influenza A (H1N1) 2009 first appeared in April, 2009 in Mexico and affected the entire world. The objective of this study is to analyze epidemiological, clinical and laboratory findings of probable or confirmed pandemic inluenza A (H1N1) 2009 adult cases who were admitted to our clinic.Methods: Eighty-five patients with pandemic influenza A (H1N1) 2009 admitted to Uludag University Hospital between November 3, 2009 and January 22, 2010 were retrospectively evaluated.Results: Of the 85 cases, 44 (51.8%) were females and 41 (48.2%) were males. The median age was 33 (17-82). 16 of cases (18.8%) were assessed as accurate, and 69 (81.2%) as probable cases of influenza. Pneumonia was diagnosed in 17 (20%) patients by evaluating clinical findings and chest X-ray. Eleven of the cases were treated in the Intensive Care Unit. Seventy-one (83.5%) of the cases were treated by oseltamivir. Mean duration of treatment was 10 days. The mortality rate of the cases was 4.7%.Conclusions: Pandemic influenza A (H1N1) 2009 perpetuates its epidemic potential as in the past years. The disease is frequently accompanied by pneumonia during its course.
  • Publication
    A case of arthropod-borne ulceroglandular tularemia
    (Aves, 2013-12-01) Kazak, Esra; Akın, Hicran; Helvacı, Safiye; KAZAK, ESRA; Akın, Hicran; Helvacı, Safiye; Uludağ Üniversitesi/Tıp Fakültesi/İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı; AAG-8459-2021; CBT-0656-2022; EXQ-2687-2022
    In Turkey, most of tularemia cases are in oropharyngeal form because the main routes of transmission are waterborne and contaminated food ingestion. On the other hand, ulceroglandular form is generally observed as a result of contact with infected animals and animal products. Arthropod-borne tularemia is very rare in Turkey. In this study, we present an arthropod-borne ulceroglandular tularemia case in Bursa province.
  • Publication
    Candida infections in intensive care unit: how to treat ?
    (Aves, 2019-08-01) Kazak, Esra; KAZAK, ESRA; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı; AAG-8459-2021
    The number of fungal infections observed in hospitalized patients has been gradually increasing in recent years. Bloodstream infections due to Candida spp. constitute the majority of hospital-acquired fungal infections. Two-thirds of all candidemias occur in patients in the intensive care units. Early initiation of appropriate treatment decreases high mortality in these cases. On the other hand, difficulty in diagnosis, economic cost of drug treatments, development of resistance, and effect of unnecessary drug use on ecology are major obstacles to the initiation of treatment. The recommendations on which conditions, in which patients, and when and which antifungal therapy should be initiated are discussed in this review.
  • Publication
    Distribution of hepatitis c virus genotypes in the south Marmara Region
    (Derman Medical Publ, 2015-03-01) Ağca, Harun; AĞCA, HARUN; Mistik, Reşit; Kazak, Esra; KAZAK, ESRA; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Mikrobiyoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı.; 0000-0002-2651-2034; ISU-9626-2023; AAG-8459-2021; AAH-4027-2021
    Aim: Hepatitis C virus (HCV) is an important caustive agent of hepatitis, cirrhosis and hepatocellular carcinoma both in our country and the world. Prognosis and response to treatment is related with the genotype of HCV which has six genotypes and over a hundred quasispecies. Knowing the HCV genotype is also important for epidemiological data. In this study we aimed to investigate the HCV genotypes of samples sent to Uludag University Hospital Microbiology Laboratory which is the reference centre in the South Marmara Region. Material and Method: This study was done retrospectively to analyse the HCV patients' sera sent to our laboratory between July 2010 and December 2012 for HCV genotyping. Artus HCV QS-RGQ PCR kit (Qiagene, Hilden, Germany) was used in Rotor-Gene Q (Qiagene, Hilden Germany) for detection of HCV RNA. HCV RNA positive samples of patients' sera were were used for genotyping by the Linear Array HCV genotyping test (Roche, NJ, USA). Results: 214 (92.6 %) of total 231 patients included in the study were genotype 1, one (0.4 %) was genotype 2, nine (3.9 %) were genotype 3 and, seven (3.4 %) were found genotype 4. Three of genotype 3 patients were of foreign nationality, two were born abroad and one of the genotype 4 patients were born abroad. Discussion: Concordant with our country data the most frequent genotype was 1, genotype 2 was seen in patients especially related with foreign countries and genotype 4 was seen rare. The importance of genotype 1, which is seen more frequent in our country and region is; resistance to antiviral treatment and prolonged treatment duration in chronic hepatitis C patients.
  • Publication
    Update on treatment options for spinal brucellosis
    (Wiley-blackwell, 2014-02-01) Ulu-Kılıç, A.; Karakas, A.; Erdem, H.; Türker, T.; İnal, A. S.; Ak, O.; Turan, H.; İnan, A.; Duygu, F.; Demiraslan, H.; Kader, C.; Sener, A.; Dayan, S.; Deveci, O.; Tekin, R.; Saltoğlu, N.; Aydın, M.; Horasan, E. S.; Gül, H. C.; Ceylan, B.; Kadanalı, A.; Karabay, O.; Karagoz, G.; Kayabaş, U.; Turhan, V.; Engin, D.; Gülsün, S.; Elaldı, N.; Alabay, S.; Kazak, E.; KAZAK, ESRA; Bursa Uludağ Üniversitesi/Tıp Fakültesi; AAG-8459-2021
    We evaluated the efficacy and tolerability of antibiotic regimens and optimal duration of therapy in complicated and uncomplicated forms of spinal brucellosis. This is a multicentre, retrospective and comparative study involving a total of 293 patients with spinal brucellosis from 19 health institutions. Comparison of complicated and uncomplicated spinal brucellosis was statistically analysed. Complicated spinal brucellosis was diagnosed in 78 (26.6%) of our patients. Clinical presentation was found to be significantly more acute, with fever and weight loss, in patients in the complicated group. They had significantly higher leukocyte and platelet counts, erythrocyte sedimentation rates and C-reactive protein levels, and lower haemoglobulin levels. The involvement of the thoracic spine was significantly more frequent in complicated cases. Spondylodiscitis was complicated, with paravertebral abscess in 38 (13.0%), prevertebral abscess in 13 (4.4%), epidural abscess in 30 (10.2%), psoas abscess in 10 (3.4%) and radiculitis in 8 (2.7%) patients. The five major combination regimens were: doxycycline 200mg/day, rifampicin 600mg/day and streptomycin 1g/day; doxycycline 200mg/day, rifampicin 600mg/day and gentamicin 5mg/kg; doxycycline 200mg/day and rifampicin 600mg/day; doxycycline 200mg/day and streptomycin 1g/day; and doxycycline 200mg/day, rifampicin 600mg/day and ciprofloxacin 1g/day. There were no significant therapeutic differences between these antibiotic groups; the results were similar regarding the complicated and uncomplicated groups. Patients were mostly treated with doxycycline and rifampicin with or without an aminoglycoside. In the former subgroup, complicated cases received antibiotics for a longer duration than uncomplicated cases. Early recognition of complicated cases is critical in preventing devastating complications. Antimicrobial treatment should be prolonged in complicated spinal brucellosis in particular.
  • Publication
    Two cases of zika virus disease diagnosed after traveling to cuba
    (Doc Design Informatics Co Ltd, 2019-04-01) Mistik, Resit; Menemenlioğlu, Dilek; Şimsek, Sümeyra; Kazak, Esra; KAZAK, ESRA; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları anabilim Dalı.
    Zika virus, is an arbovirus belonging to the Flavivirus genus first isolated from a Rhesus monkey in 1947 in Uganda. It is mainly transmitted by mosquitoes of Aedes genus. Most common signs and symptoms are fever, fatigue, headache, and rash. In this report, we report two cases of Zika virus disease with diffuse artralgias, maculopapular rash, and fatigue symptoms developing after traveling to Cuba. In the literature there were no cases of Zika virus disease reported from our country, and these are considered the first cases in Turkey.